Sionna Therapeutics, Inc. (SION) Key Metrics
SION valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $175.6M
- Enterprise value
- −$27.1M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 0.9
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
SION key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsSION returns How much profit the business earns on the capital it uses.
SION per-share figures Results divided by the shares outstanding at year-end.
SION financial health Debt, liquidity and how easily interest is covered.
SION efficiency & capital use Working capital cycle and where the cash goes.
SION valuation history
SION returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
SION debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
SION price vs earnings per share
SION key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $1.64B | — | — | — |
| Enterprise value | $1.42B | — | — | — |
| Price / book | 5.4 | — | — | — |
| Earnings yield | −4.6% | — | — | — |
| Free cash flow yield | −4.1% | — | — | — |
| Share price at fiscal year-end | $41.14 | — | — | — |
| Per share | ||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.00 |
| Earnings per share | −$1.88 | −$1.40 | −$1.07 | −$0.91 |
| Operating cash flow per share | −$1.66 | −$1.20 | −$0.99 | −$0.82 |
| Free cash flow per share | −$1.67 | −$1.20 | −$1.02 | −$0.86 |
| Cash per share | $5.90 | $3.34 | $0.87 | $1.87 |
| Book value per share | $7.68 | −$3.71 | −$2.60 | −$1.58 |
| Tangible book value per share | $7.68 | −$3.71 | −$2.60 | −$1.58 |
| Capex per share | $0.01 | $0.00 | $0.03 | $0.04 |
| Debt per share | $0.22 | $0.22 | $0.24 | — |
| Shares outstanding | 40.0M | 44.1M | 44.1M | 44.1M |
| Change in shares outstanding | −9.4% | 0.0% | 0.0% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −105.2% | — | — | — |
| Return on assets (ROA) | −29.4% | −51.9% | −67.9% | −46.1% |
| Return on tangible assets | −23.1% | −33.2% | −91.0% | −46.1% |
| Financial health | ||||
| Total debt | $8.7M | $9.7M | $10.5M | — |
| Cash & short-term investments | $235.9M | $147.5M | $38.5M | $82.6M |
| Net debt | −$227.2M | −$137.8M | −$28.0M | −$82.6M |
| Debt / equity | 0.03 | — | — | — |
| Debt / assets | 0.03 | 0.05 | 0.20 | — |
| Current ratio | 20.61 | 14.49 | 4.88 | 10.16 |
| Quick ratio | 20.61 | 14.49 | 4.88 | 10.16 |
| Working capital | $229.7M | $140.6M | $31.2M | $75.6M |
| Invested capital | $79.6M | −$301.5M | −$142.9M | −$152.5M |
| Tangible asset value | $306.8M | −$163.7M | −$114.9M | −$69.9M |
| Net current asset value | $222.3M | −$198.5M | −$127.6M | −$73.5M |
| Graham net-net per share | $5.42 | −$4.58 | −$2.91 | −$1.69 |
| Capital allocation | ||||
| Capex / depreciation | 0.58 | 0.04 | 1.91 | 15.36 |
| Efficiency | ||||
| Days payables outstanding | 551.4 | 520.5 | — | — |
| Payables turnover | 0.66 | 0.70 | — | — |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Average payables | $977,500 | $952,500 | $638,000 | $557,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from SION's annual financial statements (latest annual report filed March 2, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
SION valuation and financial ratios
Sionna Therapeutics earned a return on equity of −105.2% in fiscal 2025. It ended the year with $8.7 million of debt and $235.9 million in cash and short-term investments, a net cash position of $227.2 million.
See the SION income statement, the SION chart for price history, or the SION stock overview for the latest quote and news.
SION key metrics FAQ
What is Sionna Therapeutics's return on equity?
Sionna Therapeutics's return on equity (ROE) was −105.2% in fiscal 2025: net income of -$75.3 million on average shareholders' equity of $71.6 million.
How much debt does Sionna Therapeutics have?
Sionna Therapeutics had total debt of $8.7 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.
What is Sionna Therapeutics's free cash flow yield?
Sionna Therapeutics generated -$66.7 million of free cash flow in fiscal 2025, a free cash flow yield of −4.1% on its market value at year-end ($1.6 billion).
What is Sionna Therapeutics's current ratio?
Sionna Therapeutics's current ratio was 20.61 at the end of fiscal 2025: current assets were 20.61 times current liabilities.